Lead Program (inferred)
Inflammatory/Immune Disease (Cardiovascular focus suggested)
Phase 2/3 (inferred from 'late-stage')Active
Key Facts
Indication
Inflammatory/Immune Disease (Cardiovascular focus suggested)
Phase
Phase 2/3 (inferred from 'late-stage')
Status
Active
Company
About Tourmaline Bio
Tourmaline Bio is a late-stage, clinical-stage biotech focused on targeting the IL-6 pathway to treat inflammatory and immune diseases. The company appears to be advancing at least one product candidate through clinical development, leveraging a team of experienced entrepreneurs, physicians, and industry experts. As a private, pre-revenue company founded in 2021, it is positioned in a competitive but high-potential therapeutic area with significant unmet needs.
View full company profile